A Low Level of Darunavir Resistance–Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort

BACKGROUND: Ritonavir-boosted darunavir (DRV/r) is a protease inhibitor (PI) indicated for the treatment of naïve and pretreated HIV-infected patients since 2007. Our study aims to describe DRV/r-treated patients experiencing virological failure (VF) documented with HIV resistance testing. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaussade, Hélène, Tumiotto, Camille, Le Marec, Fabien, Leleux, Olivier, Lefèvre, Lucile, Lazaro, Estibaliz, Lafon, Marie-Edith, Nyamankolly, Elsa, Duffau, Pierre, Neau, Didier, Bellecave, Pantxika, Bonnet, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772944/
https://www.ncbi.nlm.nih.gov/pubmed/33409332
http://dx.doi.org/10.1093/ofid/ofaa567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772944/
https://www.ncbi.nlm.nih.gov/pubmed/33409332
http://dx.doi.org/10.1093/ofid/ofaa567

Ejemplares similares